Curis, Inc. (CRIS) Downgraded by Zacks Investment Research
Zacks Investment Research downgraded shares of Curis, Inc. (NASDAQ:CRIS) from a hold rating to a sell rating in a research note released on Tuesday.
According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
A number of other research analysts have also issued reports on the stock. ValuEngine lowered shares of Curis from a hold rating to a sell rating in a research note on Friday, September 15th. BidaskClub lowered shares of Curis from a hold rating to a sell rating in a research report on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. Curis presently has an average rating of Hold and an average price target of $6.50.
Shares of Curis (CRIS) traded down 1.26% during mid-day trading on Tuesday, reaching $1.57. 391,634 shares of the company were exchanged. The firm’s 50-day moving average is $1.77 and its 200-day moving average is $2.02. Curis has a 12 month low of $1.47 and a 12 month high of $3.72. The company’s market capitalization is $225.89 million.
Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The firm had revenue of $2.10 million during the quarter, compared to analyst estimates of $2.08 million. During the same quarter in the previous year, the business posted ($0.09) earnings per share. The business’s quarterly revenue was up 23.5% compared to the same quarter last year. On average, equities analysts forecast that Curis will post ($0.40) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/06/curis-inc-cris-downgraded-by-zacks-investment-research.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of CRIS. Prudential Financial Inc. bought a new position in shares of Curis during the 1st quarter worth about $105,000. American International Group Inc. lifted its holdings in shares of Curis by 7.1% during the 1st quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after acquiring an additional 4,560 shares during the period. Dynamic Technology Lab Private Ltd lifted its holdings in shares of Curis by 22.3% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 7,638 shares during the period. FMR LLC lifted its holdings in shares of Curis by 2.7% during the 1st quarter. FMR LLC now owns 15,131,961 shares of the biotechnology company’s stock worth $42,067,000 after acquiring an additional 393,582 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Curis by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock worth $13,421,000 after acquiring an additional 304,268 shares during the period. Institutional investors own 44.72% of the company’s stock.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.